Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Thoracic 3Lymphoid 1Gastrointestinal 1

Conditions

Muscular Atrophy 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × ostarine × Lymphoid × Clear all
NCT00467844 2014-07-11

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

GTx

Phase 2 Completed
159 enrolled 11 charts
GastrointestinalLymphoidThoracic

Cachexia, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Muscular Atrophy, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡